While Viridian Therapeutics Inc ( NASDAQ:VRDN ) is experiencing significant net losses, the company's strategic financial maneuvers, such as the recent private placement, are aimed at securing the necessary capital to continue its clinical development programs. The focus on advancing its lead product candidates and expanding its portfolio in the autoimmune disease space demonstrates a commitment to long-term growth and value creation for patients and shareholders.